PA8775701A1 - Antagonista de los receptores de la hormona liberadora de gonadotropina y procedimientos relacionados con ellos - Google Patents

Antagonista de los receptores de la hormona liberadora de gonadotropina y procedimientos relacionados con ellos

Info

Publication number
PA8775701A1
PA8775701A1 PA20088775701A PA8775701A PA8775701A1 PA 8775701 A1 PA8775701 A1 PA 8775701A1 PA 20088775701 A PA20088775701 A PA 20088775701A PA 8775701 A PA8775701 A PA 8775701A PA 8775701 A1 PA8775701 A1 PA 8775701A1
Authority
PA
Panama
Prior art keywords
gonadotropine
antagonist
receivers
procedures related
hormone
Prior art date
Application number
PA20088775701A
Other languages
English (en)
Inventor
Beaton Graham
Chen Mi
Richard Coon Timothy
Ewing Todd
Jiang Wanlong
Moree Willy
Wade Warren
Zhao Liren
Zhu Yun-Fei
Ashweek Neil
Rowbottom Martin
Yu Jinghua
Original Assignee
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocrine Biosciences Inc filed Critical Neurocrine Biosciences Inc
Publication of PA8775701A1 publication Critical patent/PA8775701A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

ESTA INVENCION SE REFIERE GENERALMENTE A ANTAGONISTAS DE LOS RECEPTORES DE LA HORMONA LIBERADORA DE GONADOTROPINA (GNRH) Y A PROCEDIMIENTOS DE TRATAMIENTO DE TRASTORNOS MEDIANTE LA ADMINISTRACION DE TALES ANTAGONISTAS A UN ANIMAL DE SANGRE CALIENTE QUE LOS NECESITE.
PA20088775701A 2007-04-06 2008-04-04 Antagonista de los receptores de la hormona liberadora de gonadotropina y procedimientos relacionados con ellos PA8775701A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91061907P 2007-04-06 2007-04-06

Publications (1)

Publication Number Publication Date
PA8775701A1 true PA8775701A1 (es) 2009-04-23

Family

ID=39731245

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20088775701A PA8775701A1 (es) 2007-04-06 2008-04-04 Antagonista de los receptores de la hormona liberadora de gonadotropina y procedimientos relacionados con ellos

Country Status (8)

Country Link
US (2) US8263588B2 (es)
AR (1) AR065947A1 (es)
CL (1) CL2008000986A1 (es)
PA (1) PA8775701A1 (es)
PE (1) PE20090236A1 (es)
TW (1) TW200845974A (es)
UY (1) UY31008A1 (es)
WO (1) WO2008124614A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR065948A1 (es) 2007-04-06 2009-07-15 Neurocrine Biosciences Inc Antagonistas del receptor de la hormona liberadora de gonadotropina y procedimientos relacionados con los mismos
EP2734517B1 (en) * 2011-07-18 2017-08-30 Merck Patent GmbH Benzamides

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826833A (en) * 1984-01-30 1989-05-02 Pfizer Inc. 6-(Substituted)methylene-penicillanic and 6-(substituted)hydroxymethylpenicillanic acids and derivatives thereof
JPH03173865A (ja) 1988-11-11 1991-07-29 Banyu Pharmaceut Co Ltd 置換アリルアミン誘導体、その製造法及びその用途
US5082849A (en) * 1989-07-13 1992-01-21 Huang Fu Chich Quinolinyl-benzopyran derivatives as antagonists of leukotriene D4
ES2079068T3 (es) 1990-06-29 1996-01-01 Upjohn Co 2-amino-6-fenil-4h-piran-4-onas antiateroscleroticas y antitromboticas.
GB9125515D0 (en) * 1991-11-29 1992-01-29 Merck Sharp & Dohme Therapeutic agents
US5719147A (en) * 1992-06-29 1998-02-17 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
DE69309670T2 (de) * 1992-12-28 1997-11-20 Eisai Co Ltd Heterocyclische carbonsäure-derivate, die an rar rezeptoren binden können
DE4323916A1 (de) 1993-07-16 1995-01-19 Basf Ag Substituierte 2-Phenylpyridine
CA2197785A1 (en) 1994-09-02 1996-03-14 Dieter Husken Oligonucleotide conjugates, compositions and methods for splitting ribonucleic acids
DE4439332A1 (de) * 1994-11-04 1996-05-09 Bayer Ag Substituierte Azolylsulfonylphenyluracile
CA2276278C (en) * 1997-02-27 2009-04-07 Takeda Chemical Industries, Ltd. Amine compounds, their production and use
GB9707830D0 (en) 1997-04-18 1997-06-04 Smithkline Beecham Plc Novel compounds
ATE296811T1 (de) 1997-07-11 2005-06-15 Smithkline Beecham Plc Sulfonamid-derivate als 5-ht6 receptor antagonisten und verfahren zu ihrer herstellung
US6258822B1 (en) * 1997-08-06 2001-07-10 Abbott Laboratories Urokinase inhibitors
EP1076641A1 (en) 1998-04-29 2001-02-21 Vertex Pharmaceuticals Incorporated Inhibitors of impdh enzyme
FR2779963A1 (fr) * 1998-06-22 1999-12-24 Centre Nat Rech Scient Utilisation d'un compose possedant une affinite pour le recepteur mitochondrial des benzodiazepines en therapie du cancer
ES2226485T3 (es) 1998-12-23 2005-03-16 Eli Lilly And Company Amidas aromaticas.
AU767440B2 (en) 1999-05-14 2003-11-13 Neurocrine Biosciences, Inc. Imidazo- and pyrrolo(1,2-A)pyrimid-4-ones as gonadotropin-releasing hormone receptor antagonists
MXPA02003614A (es) 1999-10-15 2002-10-23 Neurocrine Biosciences Inc Antagonistas del receptor de la hormona liberadora de ganadotropina y metodos relacionados con los mismos..
ES2383954T3 (es) 2000-01-25 2012-06-27 Neurocrine Biosciences, Inc Antagonistas del receptor de la hormona liberadora de ganodotropina y métodos relacionados con ellos
EP1152010B1 (en) * 2000-05-05 2010-04-21 Wallac Oy Oligonucleotide labeling reactants and their use
JO2654B1 (en) 2000-09-04 2012-06-17 شركة جانسين فارماسوتيكا ان. في Multiple aryl caroxa amides are useful as lipid - lowering agents
WO2002032411A2 (en) 2000-10-18 2002-04-25 Pfizer Products Inc. Combination of statins and sorbitol dehydrogenase inhibitors
WO2002034711A1 (en) 2000-10-20 2002-05-02 Biocryst Pharmaceuticals, Inc. Biaryl compounds as serine protease inhibitors
DE10059418A1 (de) * 2000-11-30 2002-06-20 Aventis Pharma Gmbh Ortho, meta-substituierte Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
RU2003132706A (ru) * 2001-04-06 2005-04-20 Байокрист Фармасьютикалз, Инк. (Us) Диариловые соединения в качестве ингибиторов сериновых протеаз
JP2002338537A (ja) 2001-05-16 2002-11-27 Mitsubishi Pharma Corp アミド化合物およびその医薬用途
JP2005500356A (ja) 2001-08-02 2005-01-06 ニューロクライン バイオサイエンシーズ， インコーポレイテッド ゴナドトロピン放出ホルモンレセプターアンタゴニスト
AU2002324586B2 (en) 2001-08-02 2008-04-24 Neurocrine Biosciences, Inc. 1,3,5-triazine-2,4,6-triones, preparation and use as gonadotropin-releasing hormone receptor antagonists
JP2005504034A (ja) 2001-08-02 2005-02-10 ニューロクライン バイオサイエンシーズ， インコーポレイテッド ゴナドトロピン放出性ホルモンレセプターアンタゴニストとしてのピリジノン誘導体およびピリダジノン誘導体
JP2005505525A (ja) 2001-08-02 2005-02-24 ニューロクライン バイオサイエンシーズ， インコーポレイテッド 性腺刺激ホルモン放出ホルモンレセプターアンタゴニストおよびそれに関連する方法
GB0215650D0 (en) * 2002-07-05 2002-08-14 Cyclacel Ltd Bisarylsufonamide compounds
CN1681487A (zh) 2002-07-15 2005-10-12 美瑞德生物工程公司 化合物、组合物及其使用方法
JP2006512314A (ja) 2002-11-01 2006-04-13 バーテックス ファーマシューティカルズ インコーポレイテッド Ｊａｋインヒビターおよび他のプロテインキナーゼインヒビターとしての組成物の使用
US20060111357A1 (en) 2002-12-11 2006-05-25 Frimurer Thomas M Quinoline compounds for use in mch receptor related disorders
AR043633A1 (es) * 2003-03-20 2005-08-03 Schering Corp Ligandos de receptores de canabinoides
US8178570B2 (en) 2003-04-09 2012-05-15 Exelixis, Inc. Tie-2 modulators and methods of use
US7429603B2 (en) 2003-04-25 2008-09-30 3-Dimensional Pharmaceuticals, Inc. C-fms kinase inhibitors
ATE557007T1 (de) 2003-07-07 2012-05-15 Neurocrine Biosciences Inc Arylpyrimidine geeignet zur behandlung von sexualhormonbedingten zuständen wie endometriose, prostatakrebs und dergleichen
CN100424078C (zh) 2003-07-07 2008-10-08 纽罗克里生物科学有限公司 作为促性激素释放激素受体拮抗剂的嘧啶-2,4-二酮衍生物
AU2004257636B2 (en) 2003-07-07 2011-01-06 Neurocrine Biosciences, Inc. Pyrimidine-2,4-dione derivatives as gonadotropin-releasing hormone receptor antagonists
AU2004261589B2 (en) 2003-07-25 2008-05-22 Novartis Ag p-38 kinase inhibitors
WO2005019188A1 (ja) * 2003-08-22 2005-03-03 Takeda Pharmaceutical Company Limited 縮合ピリミジン誘導体およびその用途
US7504401B2 (en) * 2003-08-29 2009-03-17 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
WO2005020921A2 (en) 2003-08-29 2005-03-10 Exelixis, Inc. C-kit modulators and methods of use
AR046698A1 (es) 2003-11-11 2005-12-21 Ishihara Sangyo Kaisha Derivado bifenilo o su sal, y pesticida que lo contienen como un ingrediente activo
US7119102B2 (en) * 2003-12-05 2006-10-10 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted 3-amino-thieno[2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses
JP2007519633A (ja) * 2004-01-02 2007-07-19 メルク　エンド　カムパニー　インコーポレーテッド アルキルアミノ、アリールアミノおよびスルホンアミドシクロペンチルアミド系のケモカイン受容体活性調節剤
GB0402137D0 (en) 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
WO2006078287A2 (en) 2004-05-06 2006-07-27 Plexxikon, Inc. Pde4b inhibitors and uses therefor
US7683097B2 (en) 2004-05-27 2010-03-23 Propharmacon Inc. Topoisomerase inhibitors
WO2006000358A1 (de) 2004-06-25 2006-01-05 Basf Aktiengesellschaft 2, 4, 5, 6-substituierte pyridine, verfahren zu ihrer herstellung und ihre verwendung zur bekämpfung von schadpilzen
WO2006017214A2 (en) 2004-07-12 2006-02-16 Merck & Co., Inc. Inhibitors of histone deacetylase
US7888364B2 (en) 2004-09-02 2011-02-15 Curis, Inc. Pyridyl inhibitors of hedgehog signalling
WO2006040568A1 (en) 2004-10-15 2006-04-20 Astrazeneca Ab Quinoxalines as b raf inhibitors
ATE502025T1 (de) 2004-10-19 2011-04-15 Compass Pharmaceuticals Llc Arylcarboxamide und ihre verwendung als antitumormittel
WO2006083005A1 (ja) 2005-02-03 2006-08-10 Takeda Pharmaceutical Company Limited 縮合ピリミジン誘導体およびその用途
US20090069301A1 (en) * 2005-03-03 2009-03-12 Sirtris Pharmaceuticals, Inc. Acridine and Quinoline Derivatives as Sirtuin Modulators
EP1893562A4 (en) 2005-06-14 2010-04-28 Merck Frosst Canada Ltd REVERSIBLE INHIBITORS OF MONOAMINES OXIDASES A AND B
BRPI0617436B8 (pt) * 2005-10-19 2021-05-25 Kissei Pharmaceutical derivado heterocíclico fundido, composição farmacêutica compreendendo o mesmo e usos do dito derivado na prevenção ou tratamento de doença dependente de hormônio sexual e na regulação da reprodução, contracepção ou indução de ovulação
AR065948A1 (es) * 2007-04-06 2009-07-15 Neurocrine Biosciences Inc Antagonistas del receptor de la hormona liberadora de gonadotropina y procedimientos relacionados con los mismos

Also Published As

Publication number Publication date
CL2008000986A1 (es) 2008-10-17
US8507536B2 (en) 2013-08-13
US8263588B2 (en) 2012-09-11
WO2008124614A1 (en) 2008-10-16
UY31008A1 (es) 2008-11-28
US20130040975A1 (en) 2013-02-14
US20100184741A1 (en) 2010-07-22
AR065947A1 (es) 2009-07-15
PE20090236A1 (es) 2009-03-13
TW200845974A (en) 2008-12-01

Similar Documents

Publication Publication Date Title
MX2020000690A (es) Compuestos heterociclicos como antagonistas de adenosina.
CL2019000588A1 (es) Compuestos y composiciones como inhibidores de los receptores endosomales tlr.
UY35465A (es) Nuevos compuestos como inhibidores de reorganizado durante la transfección (ret)
ES2565702R1 (es) Calidad de fuentes horarias de precisión
ES2552829R1 (es) Conmutador de distribución de tiempo
CO2018005871A2 (es) Antagonistas del receptor de la apelina (apj) mejorados y usos de los mismos
ECSP088872A (es) Antagonistas de los receptores cgrp monocíclicos sustituidos
HN2008000178A (es) Compuestos triciclicos, composiciones y procedimientos
MA43018B1 (fr) Anticorps anti-pd1 et procédés d'utilisation
CR20150296A (es) Novedosos derivados de bencimidazol como antagonistas de ep4
SV2010003494A (es) Anticuerpos anti-cxcr5 humanizados, derivados de los mismos y su uso
DOP2010000234A (es) Antagonistas n,n-disustituidos de aminoalquilbifenilo de receptores d2 de prostaglandina
ECSP067090A (es) Antagonistas del receptor de hormona relacionado con gonadotropina
AR083720A1 (es) Formulaciones adhesivas de proteina con aditivos de epiclorohidrina e isocianato
HN2006032615A (es) Derivados de carboxamida como antagonistas del receptor muscarinico
ES2547028R1 (es) Dispositivo de distribución de tiempo con antena multibanda
GT201300122A (es) Antagonistas del receptor del cgrp de piperidinona carboxamida azaindano
SV2018005631A (es) Antagonistas del receptor de cgrp
FR2944106B1 (fr) Methode de dosage de l'inositol hexaphosphate (ihp).
MX2019014114A (es) Formulaciones para el tratamiento del trastorno de estres post-traumatico.
UY35620A (es) Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
MX2020000693A (es) Compuestos de 1,8-naftiridinona, y usos de los mismos.
MX2020005483A (es) Antagonistas de ildr2 y combinaciones de los mismos.
ITUB20160628A1 (it) Procedimento per predire l'orbita di un satellite e corrispondente ricevitore di segnale satellitare
CL2014001871A1 (es) Compuestos derivados de espiroindolina sustituidos, antagonistas del receptor de la hormona liberadora de gonadotropina (gnrh); y composicion farmaceutica que los comprende.